Guest:
Dr. Joshua Brody is the Director of the Lymphoma Immunotherapy Program at the Tisch Cancer Institute at Mount Sinai. The Brody lab studies basic and applied tumor immunology for the development of cancer immunotherapies, particularly for lymphomas and melanomas. He talks about dendritic cells to improve oncolytic virus immunotherapy and in situ vaccination to improve PD-1 blockade responses.
Featured Products and Resources:
- IMMUNOLOGY2023 will be held May 11-15 in Washington, DC. Register now!
- T Cell Therapy Research: From Bench to Bedside
The Immunology Science Round Up
Enhancing T Cell Immunity to SARS-CoV-2 Variants – A new mRNA vaccine component elicits non-spike T cell responses in mice while maintaining spike immunity.
Why Infants Are Protected from Pneumonia – Enhanced opsonophagocytosis by neonatal neutrophils improves protection against Streptococcus pneumoniae in early life.
Tertiary Lymphoid Structures and Lung Cancer Immunotherapy – Researchers identified endogenous retrovirus envelope glycoproteins as a dominant antitumor antibody target in lung cancer.
Engineered Bacteria As a Melanoma Vaccine – Scientists engineered a Staphylococcus epidermidis strain to express melanoma tumor antigens and tested their ability to drive antitumor immune responses.
Image courtesy of Dr. Joshua Brody
